Table 3.

Changes in monthly headache and migraine days (Mean ± SD of MHDs and MMDs) at 60 days.

Study Report (Author and Year)	Comparator/Baseline Change in MHDs	Comparator/Baseline Change in MMDs	Intervention Dose 1 Change in MHDs	Intervention Dose 2 Change in MHDs	Intervention Dose 1 Change in MMDs	Intervention Dose 2 Change in MMDs
Armanious et al., 2021 [46]	n = 65/78 7.2 ± 8.6	n = 66/78 6.7 ± 7.3	Erenumab 70 mg n = 30/37 7.6 ± 8.3 Improvement over baseline in 81.1% of treated patients	Erenumab 140 mg n = 35/41 6.9 ± 9.0	Erenumab 70 mg n = 29/37 6.6 ± 6.5	Erenumab 140 mg n = 37/41 6.8 ± 7.9 Improvement over baseline in 90.2% of treated patients